Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...
Linsitinib is an oral small molecule that inhibits the activity of insulin-like growth factor-1 receptor (IGF-1R). It is believed that inhibition of IGF-1R may help reduce orbital inflammation and ...
As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...
LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for ...
DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ ...
Young patients with low-risk, relapsed Hodgkin lymphoma may be able to avoid transplant, data from 3 studies suggest.
We are now building a melanoma franchise through life cycle management with two Phase 3 KIMMTRAK trials ... enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase ...
The phospholipid matrix promotes mitochondrial membrane health, while R-Lipoic Acid and a PQQ supplement support the Krebs Cycle and mitochondrial ... such as creatine, beta-alanine, and caffeine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback